Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/08—Bridged systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics

Definitions

• the invention relates to new bicyclic compounds of the formula (I), ##STR3## wherein
• R 1 and R 2 are each C 1-6 alkyl group
• R 3 is an etherified hydroxy group of the formula --OR 4 , wherein R 4 is benzyl, benzhydryl or phenyl which can have a phenyl or a trihalomethyl substituent or one or more halogen substituents, or
• R 3 is an esterified hydroxy group of the formula --OCO--R 5 , namely,
• a cinnamoyloxy group which can have a halogen or one or more C 1-4 alkoxy substituents,
• a benzoyloxy group which can have a C 1-4 alkyl, phenyl or trihalomethyl group which can have a C 1-4 alkyl, phenyl or trihalomethyl substituent or one or more C 1-4 alkoxy substituents, one or more halo substituent(s) and/or a nitro substituent,
• the invention also relates to a process for the preparation of these new compounds.
• the new compounds of the formula (I) are biologically active and they exert particularly strong antiarrhythmic effects.
• the new compounds are derivatives of 3,7-diazabicyclo[3.3.1]nonane (bispidine) substituted in position 9.
• Bispidine compounds unsubstituted in position 9 have been reported in DE-OS No. 27 49,584 as CNS stimulating and anti-Parkinsonian agents and in DE-OS No. 27 26,571 as antiarrhythmic substances.
• Compositions with antiarrhythmic effects, comprising 9-unsubstituted bispidine compounds along with calcium antagonistic agents, have been disclosed in DE-OS No. 27 44,248.
• Derivatives having a cycloalkylene group or a methyl and a phenyl group in position 9 have been disclosed in DE-OS No. 26 58,558 as CNS stimulating and analgesic agents.
• rats When examining the antiarrhythmic effects, rats were pre-treated intravenously with 1 mg/kg of aconitine to provoke disorders of cardiac rhythm [Med. Exp. (Basel) 10, 93 (1964)], thereafter the test compound was administered intravenously, and the dose required to restore the rhythm in 50% (ED 50 mg/kg) was determined.
• the results of the pharmacological tests are listed in Table 1.
• the therapeutical indices (ED 50 /LD 50 ) as well as the ratio of indices (therapeutical index of the new compound:therapeutical index of Lidocaine) are also given in the Table.
• the new compounds according to the invention have no ⁇ -receptor blocking effects, whereas their local anaesthetic effects approach that of the Lidocaine. From the aspects of action mechanism it is particularly favourable that the new compounds also possess calcium antagonistic effects.
• the calcium antagonistic effect (pA 2 ) of 3-methyl-7-ethyl-9 ⁇ -(4'-chlorobenzoyloxy)-3,7-diazabicyclo[3.3.1]nonane dihydrochloride is about the same as that of the Verapramil, a compound applied successfully in the therapy (4.33-4.6 for the former substance and 4.58-4.7 for the latter).
• the prospective therapeutical dosis of the new compounds when applied for clinical treatment, is about 0.5-1 mg/kg under intravenous administration and about 10 mg/kg under oral administration.
• This amount of active agent can be administered either in a single dose or in multiple doses a day, corresponding to the disorder to be treated.
• the new compounds of the formula (I) can be prepared according to the invention so that the hydroxy group in position 9 of a compound of the formula (II), wherein R 1 and R 2 are as defined above, is esterified or etherified. More particularly,
• R 4 is as defined above and X is halogen, or
• the --O--CO--R 5 group is as defined above, or with a reactive derivative thereof, optionally in the presence of an acid binding agent, an alkali metal or another substance which catalyzes transesterification,
• the individual isomers are separated from a substance obtained as an isomeric mixture, and/or a compound of the formula (I) obtained as a free base is converted into its pharmaceutically acceptable acid addition salt, or a base of the formula (I) is liberated from its salt.
• a compound of the formula (II) is etherified with a compound of the general formula (III) on the hydroxy group in position 9 to obtain the respective ether of the formula (I). It is preferred to convert the 9-hydroxy group of the starting substance into the respective alkali metal alcoholate prior to ether formation, in order to avoid the simultaneous quaternarization of the nitrogen atoms in positions 3 and 7.
• Alkali metals or hydrodes or amides thereof such as potassium, sodium or the respective hydrides or amides, can be used as reactants for alcoholate formation.
• Sodium hydride is a preferred reactant.
• This reaction can be performed in a non-protic polar solvent, such as dimethyl formamide. The reaction proceeds easily, and can be completed by the gentle heating of the mixture.
• the resulting alcoholates are reacted preferably without isolation, directly in the reaction medium where they were formed, with the halides of the formula (III). These latter reactants are used generally in a slight excess. It is preferred to utilize a fluoride derivative as etherifying agent, since it is more difficult to perform the reaction with other halo compounds of the formula (III).
• the alcoholates react easily with the fluoro compounds of the formula (III). The reaction proceeds generally within 1-6 hours at 60°-110° C.
• the reaction mixture is processed so that, after decomposing the alcoholates with an alcohol, the mixture is treated with an aqueous acid to transfer the basic substances into the aqueous phase, from which the non-basic substances, such as the excess of the etherifying agent of the formula (III), can be removed by extraction with a water-immiscible solvent. Thereafter the aqueous phase is treated with a base to liberate the diazabicyclic compound of the formula (I) from its salt, and this free base is extracted into an appropriate solvent. The extract is evaporated and the resulting product, if liquid, is purified by vacuum distillation or, if solid, by recrystallization. The base is obtained generally in high purity, so that it can be converted into its acid addition salt without any separate purification.
• the bases can be converted into their acid addition salts, preferably dihydrochlorides, dihydrobromides or fumarates, by methods known per se.
• the reaction is performed preferably in the presence of a dehydrating agent and/or an agent for activating the carboxy group.
• acylating agent it is more preferred, however, to use a functional derivative, such as an anhydride, a halide or a C 1-5 aliphatic ester, of a compound of the formula (IV) as acylating agent.
• a functional derivative such as an anhydride, a halide or a C 1-5 aliphatic ester
• the reaction is performed preferably in the presence of an acid binding agent.
• the solvent for the reaction is a basic substance, such as a pyridine base, the excess of the solvent may also play the role of the acid binding agent.
• an inert organic solvent which appropriately dissolves both the starting substance and the product can also be applied as reaction medium, in combination with any known acid binding agent, such as triethyl amine. If no acid binding agent is applied in the reaction, it is recommended to use a non-protic organic solvent as reaction medium in which both the starting substance and the product are well soluble.
• Such solvents are the chlorinated hydrocarbons, primarily chloroform.
• the reaction is performed preferably at room temperature or under mild cooling, at 3°-10° C.
• acylating agent When a C 1-5 aliphatic ester of an acid of the formula (IV) is used as the acylating agent, it is preferred to use the acylating agent in excess and to perform the reaction in the presence of an alkali metal or another transesterification catalyst.
• catalysts e.g. alkali metals or their alcoholates, hydrides or amides can be applied.
• Metallic sodium proved to be a particularly suitable catalyst.
• 0.01 to 0.1 mole of catalyst, calculated for one mole of the diazabicyclic compound, is used in the reaction. The reaction is performed in vacuo at about 80°-100° C.; under such conditions the reaction proceeds within 1-24 hours.
• the reaction mixture is processed preferably as follows: The excess of the solvent is evaporated in vacuo, and, if the reaction is performed in the presence of a catalyst, the residue is treated to decompose the traces of catalyst. Thereafter the residue is taken up in an aqueous acid, the non-basic substances are removed from the mixture by extraction, the aqueous acidic phase is rendered alkaline, the free base of the formula (I) is separated from the aqueous mixture by extraction, and the extract is processed in a manner known per se.
• the free bases of the formula (I) are obtained generally in high purity, so that they need not be subjected to purification prior to salt formation.
• the bases are generally crystalline solids which can be purified, if desired, by recrystallization. If desired, the free bases can be converted into their acid addition salts, preferably dihydrochlorides, dihydrobromides, dimethanesulfates, etc., by methods known per se.
• the new compounds according to the invention can be converted into pharmaceutical compositions by methods well known in the art, utilizing conventional pharmaceutical carriers, diluents and/or other additives.
• the residue is dissolved in 50 ml of water, and the solution is extracted twice with 50 ml of ether, each, in order to remove the non-basic substances.
• Potassium carbonate is added to the aqueous phase until an oily substance separates, which is extracted thrice with 50 ml of diethyl ether, each.
• the etheral extracts are combined, dried over magnesium sulfate, filtered, the filtrate is evaporated, and the free base, obtained as a residue, is converted into its fumarate.
• the salt is obtained with a yield of 71.9%, related to the base.
• the aminoalcohol used as starting substance is prepared from 3,7-dimethyl-3,7-diazabicyclo[3.3.1]nonane-9-one, a known substance, by catalytic hydrogenation.
• the 9-ol compound melts at 130°-131° C. after recrystallization from hexane.
• the base is converted into its fumarate in a manner known per se.
• the salt melts at 145°-146° C. after recrystallization from ethanol.
• the dihydrochloride of the above base melts at 230°-231° C. after recrystallization from a mixture of isopropanol and methyl-ethyl-ketone.
• the isomeric mixture is treated with alcoholic hydrochloric acid in isopropanol medium.
• the ⁇ isomer which precipitates as the dihydrochloride, is separated and recrystallized twice from isopropanol.
• the salt weighing 7.7 g, is obtained with a yield of 60%; m.p.: 250° C. (under decomposition).
• the dihydrochloride salt is a colorless, crystalline substance melting at 163°-164° C. after recrystallization from isopropanol.
• the aqueous phase is rendered alkaline with potassium carbonate and extracted thrice with 50 ml of chloroform, each.
• the chloroform solutions are combined, dried over magnesium sulfate, filtered, and the filtrate is evaporated.
• the residue is crystallized from n-hexane. 3,7-Dimethyl-9-benzoyloxy-3,7-diazabicyclo[3.3.1]nonane is obtained with a yield of 42.5%; m.p.: 100°-102° C.
• the base is converted into its dihydrochloride in a manner known per se.
• the crystalline salt melts at 260° C. after recrystallization from isopropanol.
• the dihydrochloride of the above compound separates as a hemihydrate after recrystallization from methanol; m.p.: 272° C.
• the dihydrochloride of the above base prepared in a manner known per se, is a colorless crystalline substance melting at 175° C. after recrystallization from isopropanol.
• the starting substance can be prepared as follows:
• the starting substance is prepared from 3,7-di-n-butyl-3,7-diazabicyclo[3.3.1]nonane-9-one (b.p.: 123° C./7 Pa, n D 20 '1.4863) by the catalytic reduction method described in Example 13.
• the resulting 3,7-di-n-butyl-3,7-diazabicyclo[3.3.1]nonane-9-ol is recrystallized from petroleum ether (b.p.: 120° C.) and then subjected to sublimation in vacuo.
• the colourless, crystalline substance melts at 31°-32° C.
• the chloroform extracts are combined, dried over magnesium sulfate, filtered, and the filtrate is evaporated.
• the crystalline residue melts at 76°-78° C. after recrystallization from 2-butanone; yield: 99%.
• the resulting 3,7-dimethyl-9-(2'-naphthoyloxy)-3,7-diazabicyclo[3.3.1]nonane is converted into its di(methanesulfonate) in a manner known per se.
• the salt melts at 212° C. after recrystallization from ethanol.
• 0.3 g of metallic sodium are added, as small chips, to a mixture of 8 g of 3,7-dimethyl-3,7-diazabicyclo[3.3.1]nonane-9-ol and 22 g (an excess of 185%) of phenylacetic acid ethyl ester.
• the reaction mixture is maintained at a water bath heated to 90° C. for 6 hours under a vacuum of 2 kPa. The pressure is then adjusted to atmospheric, the reaction mixture is diluted with 50 ml of ether, and the basic substances are extracted twice with 75 ml of 10% aqueous hydrochloric acid solution, each.
• aqueous phases are combined, rendered alkaline with potassium carbonate, and the product, which separates as an oil, is extracted thrice with 50 ml of chloroform, each.
• the chloroform extracts are combined, dried over magnesium sulfate, filtered, the solvent is evaporated in vacuo, and the residue is distilled in vacuo.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Cardiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10957812

Family Applications (1)

Country Status (31)

Cited By (4)

Families Citing this family (3)

Family Cites Families (3)

• 1981
  • 1981-07-20 HU HU812112A patent/HU184960B/hu not_active IP Right Cessation
• 1982
  • 1982-07-06 ZA ZA824809A patent/ZA824809B/xx unknown
  • 1982-07-08 IL IL66277A patent/IL66277A/xx not_active IP Right Cessation
  • 1982-07-13 CA CA000407149A patent/CA1254208A/en not_active Expired
  • 1982-07-13 AT AT0272382A patent/AT379809B/de not_active IP Right Cessation
  • 1982-07-15 GR GR68779A patent/GR76874B/el unknown
  • 1982-07-15 CH CH4315/82A patent/CH653032A5/de not_active IP Right Cessation
  • 1982-07-15 FI FI822526A patent/FI71320C/fi not_active IP Right Cessation
  • 1982-07-16 US US06/398,801 patent/US4451473A/en not_active Expired - Lifetime
  • 1982-07-16 DD DD82241725A patent/DD202575A5/de not_active IP Right Cessation
  • 1982-07-16 DK DK319982A patent/DK160875C/da active
  • 1982-07-16 PT PT75265A patent/PT75265B/pt not_active IP Right Cessation
  • 1982-07-19 AU AU86176/82A patent/AU552770B2/en not_active Ceased
  • 1982-07-19 GB GB08220818A patent/GB2102801B/en not_active Expired
  • 1982-07-19 NL NL8202908A patent/NL8202908A/nl not_active Application Discontinuation
  • 1982-07-19 CS CS825520A patent/CS235302B2/cs unknown
  • 1982-07-19 ES ES514126A patent/ES514126A0/es active Granted
  • 1982-07-19 NO NO822485A patent/NO157421C/no unknown
  • 1982-07-19 PH PH27586A patent/PH18502A/en unknown
  • 1982-07-19 SU SU823465423A patent/SU1222197A3/ru active
  • 1982-07-19 MX MX193658A patent/MX159288A/es unknown
  • 1982-07-19 DE DE3226921A patent/DE3226921C2/de not_active Expired - Fee Related
  • 1982-07-19 YU YU157182A patent/YU45867B/sh unknown
  • 1982-07-19 FR FR8212572A patent/FR2510575B1/fr not_active Expired
  • 1982-07-19 AR AR290016A patent/AR230447A1/es active
  • 1982-07-19 IT IT22448/82A patent/IT1190920B/it active
  • 1982-07-19 SE SE8204393A patent/SE450704B/sv not_active IP Right Cessation
  • 1982-07-19 JP JP57125600A patent/JPS5849383A/ja active Granted
  • 1982-07-20 PL PL1982244329A patent/PL135814B1/pl unknown
  • 1982-07-20 PL PL1982237566A patent/PL135878B1/pl unknown
  • 1982-07-20 IN IN832/CAL/82A patent/IN155994B/en unknown
  • 1982-07-20 BE BE0/208636A patent/BE893891A/fr not_active IP Right Cessation
• 1983
  • 1983-03-14 ES ES520567A patent/ES8404354A1/es not_active Expired
  • 1983-09-22 SU SU833646755A patent/SU1272990A3/ru active

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events